Sarepta Therapeutics

@Sarepta

Commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases.

Vrijeme pridruživanja: studeni 2013.

Tweetovi

Blokirali ste korisnika/cu @Sarepta

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Sarepta

  1. Prikvačeni tweet
    13. sij

    At , SRPT CEO, Doug Ingram, underscored our commitment to advancing precision genetic medicine and for those living with .

    Poništi
  2. prije 9 sati

    We’re so proud to receive recognition from , naming SRPT Brazil a Great Place to Work. Thank you to the team members who nurture a culture of trust, teamwork and respect. Learn about career openings on our SRPT Brazil team:

    Poništi
  3. 3. velj

    Thank you to the for hosting the Family Workshop, where we joined families impacted by to share about our urgent mission to bring therapies to those living with .

    Poništi
  4. 13. sij

    Reminder: Forward looking statements are subject to risks, including those described in our webcast.

    Poništi
  5. 13. sij

    Tune in: SRPT CEO, Doug Ingram, presents at the Conference at 9:30 am PT/ 12:30 pm ET today:

    Poništi
  6. 13. sij

    We are excited to welcome industry veteran, John C. Martin, Ph.D., to SRPT’s Board of Directors. Learn more:

    Poništi
  7. 8. sij

    Save the date: The SRPT team is headed to San Francisco to present at the 38th Annual Conference on Monday, Jan. 13.

    Poništi
  8. 1. sij

    Wishing a to all. In 2019, we welcomed over 300 new team members, advanced our pipeline of over 24 programs, and had the opportunity to meet and learn from inspiring members of the patient communities.

    Poništi
  9. 23. pro 2019.

    Our mission to on behalf of patients and families drives all we do. SRPT CEO, Doug Ingram, highlights how our agreement with , helps accelerate our mission for patients. Learn more:

    Poništi
  10. 23. pro 2019.

    On our SRPT conference call, CEO, Doug Ingram, speaks to the impact our OUS licensing agreement with , for our investigational for , will have on our mission to bring therapies to patients faster. Read our press release:

    Poništi
  11. 23. pro 2019.

    Listen live: Hear from SPRT leadership regarding our new strategic licensing agreement with for SRP-9001, our investigational candidate for , in countries outside the US.

    Poništi
  12. 23. pro 2019.

    Treating 100% of Duchenne patients has always been our goal. By partnering with , the world’s largest company, we can get there faster.

    Poništi
  13. 22. pro 2019.

    : Today, we announced a strategic licensing agreement with for SRP-9001, our investigational candidate for , in countries outside the US Learn more:

    Poništi
  14. 20. pro 2019.

    We’re at the 33rd annual Family Conference in Orlando. We look forward to hearing from families and experts, and sharing about our work to develop a potential treatment for , also known as syndrome A.

    Poništi
  15. 19. pro 2019.

    Recently, we joined the Duchenne community in celebrating the of the first newborn screening test kit authorized for , empowering families with information and potentially early treatment options.

    Poništi
  16. 17. pro 2019.

    This afternoon, tune in to the SRPT Patient Support Program webinar hosted by , to hear from executive director of Patient Services, Dan Madden, about SareptAssist, a patient support program helping families navigate the process of starting and staying on therapy.

    Poništi
  17. 12. pro 2019.

    Another milestone for patients and families: We are thrilled to announce FDA approval of a treatment for a subset of patients with . We remain dedicated to finding treatments for all people living with Duchenne. Read our official announcement:

    Poništi
  18. 12. pro 2019.

    : US FDA approves new treatment for certain patients with . This approval is an important milestone that reflects our dedication to finding treatments for all people living with Duchenne.

    Poništi
  19. 12. pro 2019.

    : Each year, Jonathon films a video of himself singing, this year dedicating his performance to those who have lost their lives to . Help him reach his goal of 20,000 shares before Christmas Day:

    Poništi
  20. 3. pro 2019.

    We are beyond excited to welcome this group to the SRPT team and can’t wait to see all they will accomplish!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·